Complex therapy of atopic keratoconjunctivitis in children


The purpose of the study was to evaluate the efficacy and acceptability of the drug Restasis® in treatment of atopic keratoconjunctivitis in children. The study enrolled 16 patients (32 eyes) with atopic keratoconjunctivitis at the age from 10 to 16 years. Restasis® put on 2 drops 2 times a day during 6 months. It was determined that Restasis® is well tolerated by patients, gives significant and stable therapeutic effect confirmed by long period of clinical observation. Besides, it improves dry eye symptoms, reduces the risk of complications in long-term use of corticosteroids.

Full Text

Restricted Access

About the authors

E. V Yani

The Helmholtz Moscow Research Institute of Eye Diseases


V. V Pozdnyakova

The Helmholtz Moscow Research Institute of Eye Diseases

L. N Yakushina

The Helmholtz Moscow Research Institute of Eye Diseases

M. B Grishakova

The Helmholtz Moscow Research Institute of Eye Diseases


  1. Курбачева O.M. Поллинозы. Современные аспекты диагностики и лечения аллергических заболеваний. М.; 2009.
  2. Смирнова Г.И. Современные топические кортикостероиды в лечении аллергодерматозов у детей. Materia Medica. 2000; 1: 72-5.
  3. Балаболкин И.И., Гребенюк В.Н. Атопический дерматит у детей. М.; Медицина; 1999.
  4. Ревякина В.А. Атопический дерматит у детей: проблемы диагностики, классификации и клиники. Materia Medica. 2000;1: 41-9.
  5. Foster C.S., Calonge M. Atopic keratoconjunctivitis. Ophthalmology.1990; 98 (8): 992-1000.
  6. Power W.J., Tugal-Tutkin I., Foster C.S. Long-term follow-up patients with atopic keratoconjunctivitis. Ophthalmology. 1998; 105 (4): 637-42.



Abstract - 4

PDF (Russian) - 0



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies